Every Form 4 that Pacific Biosciences of California, Inc. (PACB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PACB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PACB filings page.
Pacific Biosciences of California, Inc. (PACB) Chief Financial Officer James R. Gibson II exercised options covering 500,000 shares on October 6, 2026, at an exercise price of $1.18 per share, acquiring 500,000 common shares. His reported option position afterward was 1,500,000 shares.
That day, he sold 661,815 shares at a weighted average price of $3.108 per share. The sales were made under a Rule 10b5-1 trading plan adopted May 22, 2026, and prices ranged from $3.00 to $3.33 per share.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) reported that President & CEO Mark Van Oene had 26,911 shares of common stock sold on 2026-08-17 in a transaction coded as a sale. A footnote states these shares were automatically sold to cover tax withholding obligations related to vesting restricted stock units, rather than a discretionary open-market sale. The weighted average sale price ranged from $1.13 to $1.15 per share, and Van Oene now holds 2,705,853 shares of PACB common stock directly.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reports that President & CEO Mark Van Oene received equity awards on August 10, 2026. He was granted a stock option for 1,967,888 shares of common stock at an exercise price of $1.15 per share, vesting in 36 equal monthly installments beginning September 10, 2026, and expiring August 10, 2036. He also received 489,130 Restricted Stock Units (RSUs), vesting in equal annual installments on August 10 of 2027, 2028, and 2029, in each case subject to continued service. Following these grants, his directly held common stock position is 2,732,764 shares.
Pacific Biosciences of California director Marshall Mohr received a new stock option grant as equity compensation. The award covers 223,492 shares of common stock at an exercise price of $1.58 per share and increases his option holdings to 223,492 derivative securities.
The option vests in monthly installments over one year on the same day of the month as the grant date or, if earlier, on the date of the next annual stockholder meeting, as long as he continues serving as a director. The option expires on June 3, 2036, giving a long-dated incentive tied to the company’s share price performance.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. director Christopher Gibson received a grant of stock options covering 74,497 shares of common stock. The options have an exercise price of $1.58 per share and expire on June 3, 2036. They vest monthly over one year, so long as he continues serving as a director through each vesting date.
PACIFIC BIOSCIENCES OF CALIFORNIA director Christopher M. Smith received a grant of stock options covering 223,492 shares of common stock. The options have an exercise price of $1.58 per share, expire on June 3, 2036, and vest monthly over one year while he continues serving as a director. Following this grant, he holds options on 223,492 shares directly.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. director Hannah Valantine received a grant of stock options covering 223,492 shares of common stock. The options have an exercise price of $1.58 per share and expire on June 3, 2036.
The options will vest monthly over one year, or earlier on the date of the next annual meeting of the company’s stockholders after the grant date, as long as she continues serving as a director. Following this grant, she holds 223,492 derivative securities directly.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported a new stock option grant for director Randall S. Livingston. He received options covering 223,492 shares of common stock at an exercise price of $1.58 per share. The options vest monthly over one year or earlier upon the next annual stockholder meeting, as long as he continues serving as a director, and expire on June 3, 2036. This filing reflects a compensation-related award, with no open-market share purchases or sales.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. director William W. Ericson received a grant of stock options covering 223,492 shares of common stock. The options have an exercise price of $1.58 per share and expire on June 3, 2036. According to the grant terms, these options vest monthly over one year, or earlier on the date of the next annual stockholder meeting, provided he continues to serve as a director through each vesting date. After this award, the filing shows 223,492 option shares held directly.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. director John F. Milligan reported a grant of 223,492 stock options. The options have an exercise price of $1.58 per share, vest monthly over one year or earlier at the next annual stockholder meeting, and expire on June 3, 2036.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. director Kathy Ordonez received a grant of stock options covering 223,492 shares of common stock. The options have an exercise price of $1.58 per share, were granted at no cost, and expire on June 3, 2036.
These options vest monthly over one year, or earlier on the date of the next annual meeting of stockholders after the grant date, as long as she continues to serve as a director through each vesting date. Following this grant, her reported stock option holdings from this award total 223,492 shares.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. director Christopher Gibson reported equity awards consisting of stock options and restricted stock units tied to his recent Board appointment. He received stock options covering 77,842 shares of Common Stock at an exercise price of $1.52 per share, expiring on April 8, 2036. One-third of these option shares will vest on March 3, 2027, with the remainder vesting in equal monthly installments over the following 24 months, contingent on continued Board service. He also acquired 57,473 shares of Common Stock represented by restricted stock units that vest in three equal annual installments on March 3 of 2027, 2028, and 2029, subject to his continued service as a director. Following these grants, he directly holds 111,386 shares of Common Stock.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. officer James R. Gibson II reported an open-market sale of 88,185 shares of common stock at a weighted average price of $1.37 per share. According to the filing, these shares were mandatorily sold to cover tax withholding obligations tied to vesting restricted stock units, and he continues to hold 1,245,663 shares directly.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. director Christopher Gibson reported equity awards connected to his election to the Board. On March 3, 2026, he received stock options for 73,087 shares at an exercise price of $0.00 and a grant of 53,913 shares of common stock represented by restricted stock units.
The RSUs vest in three equal annual installments on March 3, 2027, 2028, and 2029, conditioned on continued Board service. One‑third of the stock options vest on March 3, 2027, with the remaining options vesting in equal monthly installments over the following 24 months while he remains a director.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. officer Christian O. Henry reported an open-market sale of 12,497 shares of common stock at a weighted average price of $1.514 per share, in transactions ranging from $1.49 to $1.56, to cover tax withholding on vested restricted stock units. After these tax-related sales, he directly held 3,581,813 shares of PACB common stock.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. officer Mark Van Oene reported an open-market sale of 6,504 shares of common stock at a weighted average price of $1.514 per share. The shares were mandatorily sold to cover tax withholding obligations from vesting restricted stock units, leaving him with 2,243,634 shares held directly.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. officer Michele Farmer reported an automatic sale of common stock tied to tax withholding. On this Form 4, 2,979 shares were mandatorily sold to cover tax obligations from vesting restricted stock units at a weighted average price of $1.514 per share. After this tax-related transaction, Farmer directly held 305,948 shares of PACB common stock.
Pacific Biosciences of California, Inc. reported that officer Michele Farmer received new equity awards. On February 27, 2026, Farmer was granted a stock option covering 179,670 shares of common stock at an exercise price of $0.00 per share, and an award of 89,835 shares of common stock at $0.00 per share.
The 89,835-share award is in the form of Restricted Stock Units that vest in three equal annual installments on February 15, 2027, 2028, and 2029, if Farmer continues as a service provider. The option vests in 36 equal monthly installments beginning March 27, 2026, also conditioned on continued service.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported that executive James R. Gibson II received new equity awards. He was granted a stock option for 667,696 shares with an exercise price of $0.00 per share, and 333,848 shares of common stock as restricted stock units.
The RSUs will vest in equal annual installments on February 15 of 2027, 2028, and 2029, subject to his continued service. The stock option will vest in 36 equal monthly installments beginning on March 27, 2026, also conditioned on continued service. These are non-cash, compensation-related acquisitions rather than open-market purchases.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported that company officer Mark Van Oene acquired new equity awards. He received a stock option for 1,000,000 shares at an exercise price of $0.00 per share and a grant of 500,000 shares of common stock.
The 500,000 shares are in the form of Restricted Stock Units that vest in three equal annual installments on February 15, 2027, 2028, and 2029, contingent on continued service. The 1,000,000-share option vests in 36 equal monthly installments beginning on March 27, 2026, also subject to his continued status as a service provider.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported that officer Christian O. Henry received equity-based compensation on February 27, 2026. He was granted a stock option for 1,841,621 shares at an exercise price of $0.00 and 920,810 shares of common stock represented by restricted stock units.
The option vests in 36 equal monthly installments beginning on March 27, 2026, while the RSUs vest in three equal annual installments each February 15 of 2027, 2028, and 2029, in both cases requiring his continued service to the company.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. officer Mark Van Oene reported two transactions in the company’s common stock. On February 17, 2026, he sold 129,790 shares in open-market transactions at a weighted average price of $1.576 per share, with individual prices ranging from $1.55 to $1.70. On February 18, 2026, he sold 55,107 shares at a weighted average price of $1.629 per share, with prices ranging from $1.51 to $1.68. The filing states that the reported amount includes shares mandatorily sold to cover tax withholding obligations upon vesting of restricted stock units. After these transactions, he directly owned 1,742,638 shares, which includes 7,500 shares acquired on September 2, 2025 under the company’s 2010 Employee Stock Purchase Plan.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. officer Christian O. Henry reported open-market sales of company common stock. On February 17, he sold 331,793 shares at a weighted average price of $1.576 per share. On February 18, he sold an additional 140,874 shares at a weighted average price of $1.629 per share.
After these transactions, Henry directly held 2,814,374 shares following the February 17 sale and 2,673,500 shares following the February 18 sale, all as common stock. A footnote explains that the reported shares represent stock mandatorily sold to cover tax withholding obligations related to vesting restricted stock units, and that each sale price shown is a weighted average over a disclosed price range.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. officer Michele Farmer reported two open-market sales of common stock that were mandatorily executed to cover tax withholding on vesting restricted stock units. On February 17, 2026, Farmer sold 35,215 shares at a weighted average price of $1.576 per share. On February 18, 2026, Farmer sold 14,952 shares at a weighted average price of $1.629 per share, reflecting sale price ranges disclosed in the footnotes. After these tax-related sales, Farmer directly owned 219,092 shares of PACB common stock.